Next Article in Journal
Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer
Next Article in Special Issue
Colorectal Cancer, Liver Metastases and Biotherapies
Previous Article in Journal
An Integrative Transcriptomic and Methylation Approach for Identifying Differentially Expressed Circular RNAs Associated with DNA Methylation Change
Previous Article in Special Issue
Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine
Article

Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C

1
Department of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Gunma 375-0024, Japan
2
Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Matteo Maria Cimino
Biomedicines 2021, 9(6), 660; https://doi.org/10.3390/biomedicines9060660
Received: 20 April 2021 / Revised: 3 June 2021 / Accepted: 3 June 2021 / Published: 8 June 2021
(This article belongs to the Special Issue Liver Cancers: From Bench to Bedside)
The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated. We compared the change before and 24 weeks after the therapy with daclatasvir and asunaprevir (DCV+ASV) of M2BPGi levels with those of other fibrosis markers in 73 chronic hepatitis C cases. Moreover, we examined the association between M2BPGi levels and hepatocarcinogenesis in sustained virological response (SVR) and non-SVR cases. M2BPGi levels were significantly improved at post-treatment week 24 (PTW24) in SVR but not non-SVR cases, whereas the changes of other fibrosis markers showed the same tendency in both SVR and non-SVR cases. M2BPGi levels were well correlated with other fibrosis markers at baseline but not PTW24. The incidence of hepatocellular carcinoma (HCC) was significantly associated with M2BPGi levels at PTW24. The achievement of SVR significantly affected the improvement of M2BPGi levels that best reflected the effect of direct-acting antivirals among the fibrosis markers. Furthermore, M2BPGi levels at PTW24 were also associated with the incidence of HCC in only SVR cases. However, the rapid decrease of M2BPGi levels might reflect the amelioration of liver inflammation rather than the improvement of liver fibrosis, which should be further elucidated. View Full-Text
Keywords: mac-2 binding protein glycosylation isomer; direct acting antivirals; liver fibrosis; hepatocarcinogenesis; sustained virological response mac-2 binding protein glycosylation isomer; direct acting antivirals; liver fibrosis; hepatocarcinogenesis; sustained virological response
Show Figures

Figure 1

MDPI and ACS Style

Takakusagi, S.; Sato, K.; Marubashi, K.; Kizawa, K.; Kosone, T.; Kakizaki, S.; Takagi, H.; Uraoka, T. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines 2021, 9, 660. https://doi.org/10.3390/biomedicines9060660

AMA Style

Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines. 2021; 9(6):660. https://doi.org/10.3390/biomedicines9060660

Chicago/Turabian Style

Takakusagi, Satoshi, Ken Sato, Kyoko Marubashi, Kazuko Kizawa, Takashi Kosone, Satoru Kakizaki, Hitoshi Takagi, and Toshio Uraoka. 2021. "Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C" Biomedicines 9, no. 6: 660. https://doi.org/10.3390/biomedicines9060660

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop